GILEAD SCIENCES, INC. FY 2025 10-K, explained in plain English
Key financials — as reported
| Total revenue | $29.4B |
| Gross margin | 78.8% |
| Operating income | $10.0B |
| Net income | $8.5B |
| Diluted EPS | $6.78 |
| Cash & equivalents | — not reported |
| Total assets | $59.0B |
| Long-term debt | $24.9B |
Key takeaway
Gilead reported $29.44 billion in revenue and $8.51 billion in net income for fiscal 2025, with a 78.8% gross margin.
🔒 4 more takeaways in the full analysis
Beneath the surface
Long-term debt of $24.9 billion versus roughly $7.56 billion in cash/restricted cash and ~$3.04 billion in available-for-sale securities suggests a substantial net debt position of over $14 billion, more leveraged than the balance sheet's asset base might imply at a glance.
🔒 3 more insights a headline reader would miss
This is the free preview. The full analysis explains every line item above and includes 7 more findings — plus insider trades, activist stakes, and 8-K events for GILD.
Read the full analysis free Free account · 5 full analyses included · no card required